These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9772062)

  • 1. Sarcoidosis presenting as granulomatous colitis.
    Dumot JA; Adal K; Petras RE; Lashner BA
    Am J Gastroenterol; 1998 Oct; 93(10):1949-51. PubMed ID: 9772062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
    Letizia C; D'Ambrosio C; Agostini D; Corsi A; Boirivant M; Pallone F; Scavo D
    Ital J Gastroenterol; 1993 Jan; 25(1):23-5. PubMed ID: 8381313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions.
    Delgado J; Delgado B; Sztarkier I; Cagnano E; Sperber AD; Fich A
    Isr Med Assoc J; 2003 Dec; 5(12):897-8. PubMed ID: 14689766
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
    Neĭman KP; Rumiantsev VG
    Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association between membranous glomerulonephritis and Crohn's disease].
    Díaz Rodríguez C; Granja E; Vázquez Martul E; Sacristán F; Moreno Fernández A; González Rivero C; del Río Romero D; Trinidad JC
    Nefrologia; 2004; 24(4):368-71. PubMed ID: 15455498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy to reduce postoperative Crohn's disease recurrence.
    Achkar JP; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1139-46. PubMed ID: 10811318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
    Jovanovic IR; Milosavjevic TN; Jankovic GP; Micev MM; Dugalic PD; Saranovic D; Ugljesic MM; Popovic DV; Bulajic MM
    Med Sci Monit; 2001; 7(1):137-41. PubMed ID: 11208510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.
    González Carro P; Pérez Roldán F; Roncero García Escribano O; Lafuente R; Legaz Huidobro ML; Amigo Echenagusía A
    J Clin Apher; 2006 Dec; 21(4):249-51. PubMed ID: 16607627
    [No Abstract]   [Full Text] [Related]  

  • 13. Current treatment for prevention of relapse and recurrence in Crohn's disease.
    Prantera C; Scribano ML
    Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy of Crohn disease].
    Niemelä S
    Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446
    [No Abstract]   [Full Text] [Related]  

  • 15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease].
    Nos P; Hinojosa J; Aguilera V; Molés JR; Pastor M; Ponce J; Berenguer J
    Gastroenterol Hepatol; 2000 Oct; 23(8):374-8. PubMed ID: 11227650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

  • 18. Mesalazine-induced aplastic anemia.
    Wiesen A; Wiesen J; Limaye S; Kaushik N
    Am J Gastroenterol; 2009 Apr; 104(4):1063. PubMed ID: 19259075
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacologic therapy of Crohn's disease and ulcerative colitis].
    Banai J
    Orv Hetil; 2000 May; 141(22):1171-7. PubMed ID: 10853345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe exudative ascites as an initial presentation of Crohn's disease.
    Tekin F; Vatansever S; Ozütemiz O; Musoğlu A; Ilter T
    Turk J Gastroenterol; 2005 Sep; 16(3):171-3. PubMed ID: 16245232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.